- Home
- FURY vs EPIX Comparison
FURY vs EPIX Comparison
Compare FURY & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- EPIX
- Stock Information
- Founded
- FURY 2008
- EPIX 2009
- Country
- FURY Canada
- EPIX Canada
- Employees
- FURY N/A
- EPIX N/A
- Industry
- FURY Precious Metals
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- FURY Basic Materials
- EPIX Health Care
- Exchange
- FURY Nasdaq
- EPIX Nasdaq
- Market Cap
- FURY 60.5M
- EPIX 65.3M
- IPO Year
- FURY N/A
- EPIX N/A
- Fundamental
- Price
- FURY $0.39
- EPIX $1.79
- Analyst Decision
- FURY Strong Buy
- EPIX Hold
- Analyst Count
- FURY 1
- EPIX 3
- Target Price
- FURY $1.10
- EPIX $2.00
- AVG Volume (30 Days)
- FURY 154.5K
- EPIX 186.2K
- Earning Date
- FURY 05-13-2025
- EPIX 05-13-2025
- Dividend Yield
- FURY N/A
- EPIX N/A
- EPS Growth
- FURY N/A
- EPIX N/A
- EPS
- FURY N/A
- EPIX N/A
- Revenue
- FURY N/A
- EPIX N/A
- Revenue This Year
- FURY N/A
- EPIX N/A
- Revenue Next Year
- FURY N/A
- EPIX N/A
- P/E Ratio
- FURY N/A
- EPIX N/A
- Revenue Growth
- FURY N/A
- EPIX N/A
- 52 Week Low
- FURY $0.35
- EPIX $1.40
- 52 Week High
- FURY $0.57
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- FURY 53.97
- EPIX 69.44
- Support Level
- FURY $0.35
- EPIX $1.42
- Resistance Level
- FURY $0.41
- EPIX $1.88
- Average True Range (ATR)
- FURY 0.02
- EPIX 0.10
- MACD
- FURY 0.00
- EPIX 0.03
- Stochastic Oscillator
- FURY 73.77
- EPIX 81.32
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.